Comments and answers:
1. As the authors pointed out, this therapy is worried about high recurrence rate. The authors should show an imaging at 14 months or more long-term after this therapy.

Our answer: Thank you for the comment. We payed much attention to the follow-ups. But the patient only showed up in the outpatient department in March 2021, and then regularly reviewed abdominal US in local hospitals and keep contact with us on telephone due to COVID-19. Since COVID-19 is spreading in Beijing recently, we failed to get a high-resolution US imaging from the patient despite our best efforts. In future follow-ups, we will keep contact with the patient and alert potential recurrence.

2. p9, line 18. The authors mentioned the safety and efficacy of this therapy. However, I think this is an overstatement since this paper is a case report.

Our answer: Thank you for the comment. We have revised it and stated that more studies are needed for approving the safety and efficacy of this therapy (as highlighted in p9).